Abstract Submission Guidelines
10th Annual International Coronary Congress
SUBMISSION DEADLINE: Monday, 10 June, 2024
23:59 Eastern Time (New York)
Abstract and Cases deemed appropriate for presentation before the International CoronaryCongress (ICC) will have the following characteristics:


Original, new and significant scientific work.
Major updates and/or significant follow-up on established procedures and/or research.
Additional definition of previous studies that modify in a major way an understanding oftechniques or technologies.
The submitted Abstract should not be similar to work submitted to, or under consideration
by, other organizations and/or journals.
ABSTRACT PREPARATION AND SUBMISSION INSTRUCTIONS

oAbstracts must be submitted electronically. The deadline is Monday, 10 June, 2024 at
23:59, Eastern Time (New York).

oTotal abstract word limit is 350. There is a minimum word count of 50 words.

oThere are two presentation formats: Oral Presentation and e-Poster Presentation. Whensubmitting an abstract, one of the following options must be selected:
Oral Presentation
Oral or e-Poster Presentation
e-Poster Presentation Only

Please note the final presentation format will be determined by the ISCAS Program Committee.
ABSTRACT FORMAT
All abstracts must be structured using the following section headings:
Objective: A brief statement of the purpose of the study and the current state of research in thefield.
Methods: The methods of study or experimental approach should be clearly, but briefly, defined
Results: A summary of the results of the study, including sufficient details to support thoseconclusions. These may be presented in a brief table.

Conclusions: A statement concerning the significance of the work and its possible implications
for clinical practice and for future research.
ABSTRACT FORMAT (CONTINUED)
Type the abstract in English within the box provided. The abstract title must be in title
case, flush with the left margin of the box. Use upper and lower case letters as
appropriate for abbreviations in the title.
Up to one (1) table, image or figure may be used within your abstract.
No reference should be made in the abstract to the names or institutions of the authors.
Accepted abstracts will appear in the program and online as submitted. Please double
check your work to ensure it is complete.

ABSTRACT SUBMISSION CATEGORIESTo facilitate the review and selection process, abstracts should be submitted in one of the listedcategories. There are no quotas or caps on any of the categories; all complete submissions willbe reviewed.
CABG in Women
Off-pump CABGBest Practices in Cardiopulmonary Bypass and Cardioplegia
Minimally Invasive + Robotic CABG (MIDCAB/MICS/LAST) + Hybrid CABG
Conduit Configuration, Harvesting Techniques and Alternative Conduits
Novel Techniques and Technologies in CABGERAS after CABG/CABG Pathways
Outcomes in CABG
Atrial Fibrillation Management in CABGHeart Failure and CABG
Coronary Imaging Angiography, CT FFR, MRI, Nuclear Stress
Relative Efficacy of CABG and PCI
Management of Ischemic Mitral Regurgitation during CABG
Challenging CABG Cases
Infection Prevention and Treatment
Management of CAD
Quality Control in CABG
Prevention and Treatment of Surgical Site Infection in CABG
Coronary Misc.

DISCLOSURE REQUIREMENTS
One of the founding principles of the ICC is the acknowledgement of interaction between
industry and surgeons to facilitate rapid development of technology and techniques to treat
heart valve disease. In that endeavor, a surgeon may become financially involved with thecompany that translates his or her idea into reality. The ICC does not object to that relationship,
but requires that all those submitting abstracts and presenting papers disclose financial orconsulting relationships with companies that may be involved with production or marketing oftechnology being discussed.
The need for disclosure extends to unrestricted laboratory grants. In addition, any off-label use ofan FDA-approved product, or any use of a non-FDA approved device must be disclosed. When
you complete your abstract submission, you will be required to complete disclosure information
for ALL authors.
Disclose any relevant financial relationships for any and all authors listed in the title string.
Specific definitions are included in the online submission process.
Be prepared to speak with the Program Committee Chair to resolve any disclosed
conflicts.
In the event your work is selected for presentation, list all disclosed conflicts on a slide
placed at the beginning of your presentation.

In order to comply with the ACCME Updated Standards for Commercial Support, Cine-Med as
the accredited CME provider of this activity, has implemented a disclosure process to ensurethat anyone who is in a position to control the content of the educational activity has disclosed
to us all relevant financial relationships with any commercial interest as it pertains to the contentof the presentation. The goal of this process is not to exclude people who have conflicts, but tomanage these conflicts while benefiting from your expertise.
Should it be determined that a conflict of interest exists as a result of a financial relationship you
may have, you will be contacted and methods to resolve the conflict will be discussed with you.
In addition, all affirmative disclosures must be revealed by a slide at the beginning of thepresentation and must be acknowledged from the podium. Failure or refusal to disclose or theinability to resolve the identified conflict may result in the withdrawal of the invitation toparticipate.
If you have difficulty uploading files or navigating the abstract submission site, please contact
technical assistance:
support@abstractsonline.com or 1-217-398-1792
If you have questions regarding submission policies, presentation formats and authorrequirements please contact the ICC meetings department:
meetings@internationalcoronarycongress.com or 1-978-927-8330